Intraoperative radiation therapy with the photon radiosurgery system in locally advanced and recurrent rectal cancer: retrospective review of the Cleveland clinic experience

Radiation Oncology

John H Suh¹  Feza H Remzi²  David W Dietz²  F Christopher Deibel¹  Arul Mahadevan³  Neil Woody¹  Matthew Kolar¹  Chandana A Reddy¹  Susan Guo¹ 

[1] Department of Radiation Oncology, Cleveland Clinic, T28 9500 Euclid Ave., Cleveland, OH, 44195, USA;Department of Colorectal Surgery, Cleveland Clinic, Cleveland, OH, USA;Department of Radiation Oncology, Lahey Clinic, Peabody, MA, USA

关键词: Radiation tolerance;    Salvage;    Local disease relapse;    Intraoperative radiation therapy;    Colorectal cancer;   

Others  :  1160806
DOI  :  10.1186/1748-717X-7-110

 received in 2012-02-17, accepted in 2012-07-20,  发布年份 2012

【 摘 要 】

Background

Patients with locally advanced or recurrent rectal cancer often require multimodality treatment. Intraoperative radiation therapy (IORT) is a focal approach which aims to improve local control.

Methods

We retrospectively reviewed 42 patients treated with IORT following definitive resection of a locally advanced or recurrent rectal cancer from 2000–2009. All patients were treated with the Intrabeam® Photon Radiosurgery System (PRS). A dose of 5 Gy was prescribed to a depth of 1 cm (surface dose range: 13.4-23.1, median: 14.4 Gy). Median survival times were calculated using Kaplan-Meier analysis.

Results

Of 42 patients, 32 had recurrent disease (76%) while 10 had locally advanced disease (24%). Eighteen patients (43%) had tumors fixed to the sidewall. Margins were positive in 19 patients (45%). Median follow-up after IORT was 22 months (range 0.2-101). Median survival time after IORT was 34 months. The 3-year overall survival rate was 49% (43% for recurrent and 65% for locally advanced patients). Local recurrence was evaluable in 34 patients, of whom 32% failed. The 1-year local recurrence rate was 16%. Distant metastasis was evaluable in 30 patients, of whom 60% failed. The 1-year distant metastasis rate was 32%. No intraoperative complications were attributed to IORT. Median duration of IORT was 35 minutes (range: 14–39). Median discharge time after surgery was 7 days (range: 2–59). Hydronephrosis after IORT occurred in 10 patients (24%), 7 of whom had documented concomitant disease recurrence.

Conclusions

The Intrabeam® PRS appears to be a safe technique for delivering IORT in rectal cancer patients. IORT with PRS marginally increased operative time, and did not appear to prolong hospitalization. Our rates of long-term toxicity, local recurrence, and survival rates compare favorably with published reports of IORT delivery with other methods.

【 授权许可】

   
2012 Guo et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

【 参考文献 】

• [1]Peeters KC, Marijnen CA, Nagtegaal ID, Kranenbarg EK, Putter H, Wiggers T, Rutten H, Pahlman L, Glimelius B, Leer JW, van de Velde CJ: The TME trial after a median follow-up of 6 years: increased local control but no survival benefit in irradiated patients with resectable rectal carcinoma. Ann Surg 2007, 246:693-701.
• [2]Bosset JF, Collette L, Calais G, Mineur L, Maingon P, Radosevic-Jelic L, Daban A, Bardet E, Beny A, Ollier JC: Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med 2006, 355:1114-1123.
• [3]Bujko K, Nowacki MP, Nasierowska-Guttmejer A, Michalski W, Bebenek M, Kryj M: Long-term results of a randomized trial comparing preoperative short-course radiotherapy with preoperative conventionally fractionated chemoradiation for rectal cancer. Br J Surg 2006, 93:1215-1223.
• [4]Sauer R, Becker H, Hohenberger W, Rodel C, Wittekind C, Fietkau R, Martus P, Tschmelitsch J, Hager E, Hess CF, et al.: Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 2004, 351:1731-1740.
• [5]Valentini V, Morganti AG, De Franco A, Coco C, Ratto C, Battista Doglietto G, Trodella L, Ziccarelli L, Picciocchi A, Cellini N: Chemoradiation with or without intraoperative radiation therapy in patients with locally recurrent rectal carcinoma: prognostic factors and long term outcome. Cancer 1999, 86:2612-2624.
• [6]Suzuki K, Gunderson LL, Devine RM, Weaver AL, Dozois RR, Ilstrup DM, Martenson JA, O'Connell MJ: Intraoperative irradiation after palliative surgery for locally recurrent rectal cancer. Cancer 1995, 75:939-952.
• [7]Vaidya JS, Joseph DJ, Tobias JS, Bulsara M, Wenz F, Saunders C, Alvarado M, Flyger HL, Massarut S, Eiermann W, et al.: Targeted intraoperative radiotherapy versus whole breast radiotherapy for breast cancer (TARGIT-A trial): an international, prospective, randomised, non-inferiority phase 3 trial. Lancet 2010, 376:91-102.
• [8]Haddock MG, Miller RC, Nelson H, Pemberton JH, Dozois EJ, Alberts SR, Gunderson LL: Combined modality therapy including intraoperative electron irradiation for locally recurrent colorectal cancer. Int J Radiat Oncol Biol Phys 2011, 79:143-150.
• [9]Lindel K, Willett CG, Shellito PC, Ott MJ, Clark J, Grossbard M, Ryan D, Ancukiewicz M: Intraoperative radiation therapy for locally advanced recurrent rectal or rectosigmoid cancer. Radiother Oncol 2001, 58:83-87.
• [10]Wiig JN, Tveit KM, Poulsen JP, Olsen DR, Giercksky KE: Preoperative irradiation and surgery for recurrent rectal cancer. Will intraoperative radiotherapy (IORT) be of additional benefit? A prospective study. Radiother Oncol 2002, 62:207-213.
• [11]Dresen RC, Gosens MJ, Martijn H, Nieuwenhuijzen GA, Creemers GJ, Daniels-Gooszen AW, van den Brule AJ, van den Berg HA, Rutten HJ: Radical resection after IORT-containing multimodality treatment is the most important determinant for outcome in patients treated for locally recurrent rectal cancer. Ann Surg Oncol 2008, 15:1937-1947.
• [12]Abuchaibe O, Calvo FA, Azinovic I, Aristu J, Pardo F, Alvarez-Cienfuegos J: Intraoperative radiotherapy in locally advanced recurrent colorectal cancer. Int J Radiat Oncol Biol Phys 1993, 26:859-867.
• [13]Bussieres E, Gilly FN, Rouanet P, Mahe MA, Roussel A, Delannes M, Gerard JP, Dubois JB, Richaud P: Recurrences of rectal cancers: results of a multimodal approach with intraoperative radiation therapy. French Group of IORT. Intraoperative radiation therapy. Int J Radiat Oncol Biol Phys 1996, 34:49-56.
• [14]Mathis KL, Nelson H, Pemberton JH, Haddock MG, Gunderson LL: Unresectable colorectal cancer can be cured with multimodality therapy. Ann Surg 2008, 248:592-598.
• [15]Willett CG, Shellito PC, Tepper JE, Eliseo R, Convery K, Wood WC: Intraoperative electron beam radiation therapy for primary locally advanced rectal and rectosigmoid carcinoma. J Clin Oncol 1991, 9:843-849.
• [16]Diaz-Gonzalez JA, Calvo FA, Cortes J, Garcia-Sabrido JL, Gomez-Espi M, Del Valle E, Munoz-Jimenez F, Alvarez E: Prognostic factors for disease-free survival in patients with T3-4 or N + rectal cancer treated with preoperative chemoradiation therapy, surgery, and intraoperative irradiation. Int J Radiat Oncol Biol Phys 2006, 64:1122-1128.
• [17]Krempien R, Roeder F, Oertel S, Roebel M, Weitz J, Hensley FW, Timke C, Funk A, Bischof M, Zabel-Du Bois A, et al.: Long-term results of intraoperative presacral electron boost radiotherapy (IOERT) in combination with total mesorectal excision (TME) and chemoradiation in patients with locally advanced rectal cancer. Int J Radiat Oncol Biol Phys 2006, 66:1143-1151.
• [18]Lyadov KV SS, Krymskiy VA, Krymskiy AV: Improvement of curativity of video-assisted surgery for colorectal cancer due to intra-operative contact radiotherapy using the Intrabeam system. In Rev Cancer 2008, 2008:8.